These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 25769784)

  • 1. Pharmacokinetic interactions between telaprevir and antiretroviral drugs in HIV/HCV-coinfected patients with advanced liver fibrosis and prior HCV non-responders.
    Milazzo L; Cattaneo D; Calvi E; Gervasoni C; Mazzali C; Ronzi P; Peri AM; Ridolfo AL; D'Avolio A; Antinori S
    Int J Antimicrob Agents; 2015 May; 45(5):545-9. PubMed ID: 25769784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of ritonavir in the drug interactions between telaprevir and ritonavir-boosted atazanavir.
    Gutierrez-Valencia A; Ruiz-Valderas R; Torres-Cornejo A; Viciana P; Espinosa N; Castillo-Ferrando JR; Lopez-Cortes LF
    Clin Infect Dis; 2014 Jan; 58(2):268-73. PubMed ID: 24145880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Darunavir and telaprevir drug interaction: total and unbound plasma concentrations in HIV/HCV-coinfected patients with cirrhosis.
    Curran A; Guiu JM; Ribera E; Crespo M
    J Antimicrob Chemother; 2014 May; 69(5):1434-6. PubMed ID: 24363317
    [No Abstract]   [Full Text] [Related]  

  • 4. Review of drug interactions with telaprevir and antiretrovirals.
    van Heeswijk RP; Beumont M; Kauffman RS; Garg V
    Antivir Ther; 2013; 18(4):553-60. PubMed ID: 23344266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of lead-in silibinin and subsequent triple therapy in difficult-to-treat HIV/hepatitis C virus-coinfected patients.
    Braun DL; Rauch A; Durisch N; Eberhard N; Anagnostopoulos A; Ledergerber B; Metzner KJ; Böni J; Weber R; Fehr J
    HIV Med; 2014 Nov; 15(10):625-30. PubMed ID: 24894776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing treatment in HIV/HCV coinfection.
    Puoti M; Rossotti R; Travi G; Panzeri C; Morreale M; Chiari E; Cocca G; Orso M; Moioli MC
    Dig Liver Dis; 2013 Sep; 45 Suppl 5():S355-62. PubMed ID: 24091116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France.
    Aherfi S; Solas C; Motte A; Moreau J; Borentain P; Mokhtari S; Botta-Fridlund D; Dhiver C; Portal I; Ruiz JM; Ravaux I; Bregigeon S; Poizot-Martin I; Stein A; Gérolami R; Brouqui P; Tamalet C; Colson P
    J Med Virol; 2014 Nov; 86(11):1868-76. PubMed ID: 25052594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Etravirine-based antiretroviral therapy in HIV/hepatitis C virus coinfected advanced fibrosis patients receiving triple therapy against hepatitis C virus with telaprevir.
    Ramirez ML; Vargas FX; González-Garcia J; Quereda C; Pérez-Elías MJ; de Cea AM; Barros C; Condés E; Moreno JS; Santos I; Torralba M; Aldamiz-Echevarria T; Moreno A
    AIDS; 2014 Oct; 28(16):2487-9. PubMed ID: 25265233
    [No Abstract]   [Full Text] [Related]  

  • 9. Boceprevir and telaprevir-based regimens for the treatment of hepatitis C virus in HIV/HCV coinfected patients.
    Beste LA; Green PK; Ioannou GN
    Eur J Gastroenterol Hepatol; 2015 Feb; 27(2):123-9. PubMed ID: 25503739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Telaprevir and ribavirin interaction: higher ribavirin levels are not only due to renal dysfunction during triple therapy.
    Gutierrez-Valencia A; Ruiz-Valderas R; Ben-Marzouk-Hidalgo OJ; Torres-Cornejo A; Espinosa N; Castillo-Ferrando JR; Viciana P; Lopez-Cortes LF
    Antimicrob Agents Chemother; 2015; 59(6):3257-62. PubMed ID: 25801562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C.
    Macías J; Mira JA; López-Cortés LF; Santos I; Girón-González JA; González-Serrano M; Merino D; Hernández-Quero J; Rivero A; Merchante N; Trastoy M; Carrillo-Gómez R; Arizcorreta-Yarza A; Gómez-Mateos J; Pineda JA
    Antivir Ther; 2006; 11(7):839-46. PubMed ID: 17302246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Challenges in the treatment of chronic hepatitis C in the HIV/HCV-coinfected patient.
    Rodríguez-Torres M
    Expert Rev Anti Infect Ther; 2012 Oct; 10(10):1117-28. PubMed ID: 23199398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advanced liver fibrosis in HIV/HCV-coinfected patients on antiretroviral therapy.
    Fuster D; Planas R; Muga R; Ballesteros AL; Santos J; Tor J; Sirera G; Guardiola H; Salas A; Cabré E; Ojanguren I; Barluenga E; Rey-Joly C; Clotet B; Tural C
    AIDS Res Hum Retroviruses; 2004 Dec; 20(12):1293-7. PubMed ID: 15650421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug-Drug Interactions of Glecaprevir and Pibrentasvir Coadministered With Human Immunodeficiency Virus Antiretrovirals.
    Kosloski MP; Oberoi R; Wang S; Viani RM; Asatryan A; Hu B; Ding B; Qi X; Kim EJ; Mensa F; Kort J; Liu W
    J Infect Dis; 2020 Jan; 221(2):223-231. PubMed ID: 31504702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors associated with guideline-based hepatitis C virus (HCV) treatment initiation in HIV/HCV-coinfected patients: role of comorbidities and physicians' perceptions.
    Winnock M; Bani-Sadr F; Pambrun E; Loko MA; Carrieri P; Neau D; Morlat P; Marchou B; Dabis F; Salmon D;
    HIV Med; 2013 Aug; 14(7):430-6. PubMed ID: 23461846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Raltegravir pharmacokinetics in HIV/HCV-coinfected patients with advanced liver cirrhosis (Child-Pugh C).
    Hernández-Novoa B; Moreno A; Pérez-Elías MJ; Quereda C; Dronda F; Casado JL; Madrid-Elena N; Aguilar M; Fumero E; Moltó J; Moreno S
    J Antimicrob Chemother; 2014 Feb; 69(2):471-5. PubMed ID: 24097843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nevirapine pharmacokinetics in HIV-infected and HIV/HCV-coinfected individuals.
    Vogel M; Bertram N; Wasmuth JC; Wyen C; Voigt E; Schwarze-Zander C; Sudhop T; Fätkenheuer G; Rockstroh JK; Reichel C
    J Antimicrob Chemother; 2009 May; 63(5):988-91. PubMed ID: 19270314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of hepatitis C and liver fibrosis on antiretroviral plasma drug concentrations in HIV-HCV co-infected patients: the HEPADOSE study.
    Dominguez S; Ghosn J; Peytavin G; Guiguet M; Tubiana R; Valantin MA; Murphy R; Bricaire F; Benhamou Y; Katlama C
    J Antimicrob Chemother; 2010 Nov; 65(11):2445-9. PubMed ID: 20813809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prevalence of potential interactions between antiretroviral therapy and boceprevir or telaprevir in human immunodeficiency virus-hepatitis C virus coinfected patients].
    González-Colominas E; Solà R; Barrantes-González M; Salas E
    Enferm Infecc Microbiol Clin; 2013 May; 31(5):350-1. PubMed ID: 23182365
    [No Abstract]   [Full Text] [Related]  

  • 20. HIV-HCV co-infection facing HCV protease inhibitor licensing: implications for clinicians.
    Ingiliz P; Rockstroh JK
    Liver Int; 2012 Sep; 32(8):1194-9. PubMed ID: 22510096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.